Home > Cardiology > HFA 2022 > HFA 2022 Highlights Podcast

HFA 2022 Highlights Podcast

Presented By
Dr Robert van den Heuvel, Medicom
Conference
HFA 2022


In this episode (16:07), Medicom’s correspondent covers 6 presentations from the Heart Failure Congress (HFA 2022), held virtually and in-person from 21-24 May 2022.
The topics discussed are:
  1.  First non-adrenergic drug to show benefit on BP in pre-cardiogenic shock
    In a pilot study, istaroxime significantly increased the systolic blood pressure (SBP) of patients with pre-cardiogenic shock. The agent was well-tolerated and was not associated with worsening arrhythmias or renal function. These results encourage further investigation of this non-adrenergic agent.

  2. GALACTIF-HF: Omecamtiv mecarbil option for HFrEF patients with low SBP
    Although patients with heart failure with reduced ejection fraction (HFrEF) and low systolic blood pressure (SBP) displayed a higher risk of HF outcomes in a subanalysis of the GALACTIC-HF trial, treatment with omecamtiv mecarbil reduced this risk more distinctively than in those with a higher SBP. Since placebo and omecamtiv mecarbil showed similar safety profiles, this agent may be a valid option for the hard-to-treat population of patients with HFrEF and low SBP.

  3. Should ATTR-CM be added to differential diagnosis of patients with HF?
    Amyloidosis was determined to be the cause of heart failure (HF) in approximately 20% of the patients treated in the internal medicine departments of 24 Spanish hospitals. According to the authors, transthyretin amyloid cardiomyopathy (ATTR-CM) should be included in the differential diagnosis of elderly patients with HF and myocardial thickening.

  4. Cardiac contractility modulation therapy promising for patients with HFpEF
    A pilot study assessing cardiac contractility modulation (CCM) therapy in patients with heart failure and preserved ejection fraction (HFpEF) displayed a significant improvement in the health status of patients following this therapy. Further studies are warranted to establish the applicability of CCM in patients with HFpEF.

  5. DAPA-HF: Dapagliflozin safe and efficacious in frail patients
    Dapagliflozin, added to guideline-recommended therapies, was associated with a reduction of major cardiovascular events and all-cause death in patients with heart failure and reduced ejection fractions (HFrEF) irrespective of frailty status. Furthermore, the drug was well tolerated regardless of frailty status. These results may aid physicians who are reluctant to prescribe medications to frail patients.

  6. REBALANCE-HF: Encouraging results of GSN ablation in HFpEF
    Preliminary data from the REBALANCE-HF roll-in cohort demonstrated positive safety and efficacy results of splanchnic ablation for volume management (SAVM) via greater splanchnic nerve (GSN) ablation for patients with heart failure and preserved ejection fraction (HFpEF). The procedure was associated with reductions in pulmonary capillary wedge pressure (PCWP) during exercise and improvements in the health status of patients.
Enjoy listening!

Copyright ©2022 Medicom Medical Publishers

Posted on